Skip to main content
. 2014 Oct 2;143(3):416–427. doi: 10.1111/imm.12319

Figure 1.

Figure 1

Schematic of murine interleukin-4 (IL-4/IL-13 dual antagonist. (a) Configuration of IL-4/IL-13 dual antagonist, from N-terminal mouse IL-13Rα2 extracellular domain (ECD) to C-terminal scFv of anti-mouse IL-4 monoclonal antibody (mAb) mu11B11. (b) Schematic indicating overall structure of the IL-4/IL-13 dual antagonist, with two binding sites for each cytokine. (c) Cell-based IC50 and SPR-derived Kd values for anti-mouse IL-4 mAb mu11B11, sIL-13Rα2-Fc, and bifunctional IL-4/IL-13 antagonist. IC50 values were derived from a signal transducer and activator of transcription 6 (STAT6) phosphorylation bioassay using BaF3 cells expressing murine IL-13Rα1 and IL-4Rα.